Selected research
Market Outlook & Growth Opportunities
Global Acquired Immunodeficiency Syndrome Market Outlook and Growth Opportunities 2026
Market perspective
The global Acquired Immunodeficiency Syndrome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Acquired Immunodeficiency Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Acquired Immunodeficiency Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Acquired Immunodeficiency Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Acquired Immunodeficiency Syndrome market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Acquired Immunodeficiency Syndrome market include Takeda, Sanofi, Novartis, Pfizer, Amgen, Merck KGaA, Daiichi Sankyo Company, Biogen and AstraZeneca Eli Lilly and Company, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Acquired Immunodeficiency Syndrome market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Acquired Immunodeficiency Syndrome and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Acquired Immunodeficiency Syndrome revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acquired Immunodeficiency Syndrome market.
Acquired Immunodeficiency Syndrome Segment by Company
Takeda
Sanofi
Novartis
Pfizer
Amgen
Merck KGaA
Daiichi Sankyo Company
Biogen
AstraZeneca Eli Lilly and Company
Actelion
Acquired Immunodeficiency Syndrome Segment by Type
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Acquired Immunodeficiency Syndrome Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
Acquired Immunodeficiency Syndrome Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Acquired Immunodeficiency Syndrome status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Acquired Immunodeficiency Syndrome key companies, revenue, market share, and recent developments.
3. To split the Acquired Immunodeficiency Syndrome breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Acquired Immunodeficiency Syndrome market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Acquired Immunodeficiency Syndrome significant trends, drivers, influence factors in global and regions.
6. To analyze Acquired Immunodeficiency Syndrome competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acquired Immunodeficiency Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acquired Immunodeficiency Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acquired Immunodeficiency Syndrome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acquired Immunodeficiency Syndrome industry.
Chapter 3: Detailed analysis of Acquired Immunodeficiency Syndrome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Acquired Immunodeficiency Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Acquired Immunodeficiency Syndrome in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Acquired Immunodeficiency Syndrome Industry Trends
Table 2. Acquired Immunodeficiency Syndrome Industry Drivers
Table 3. Acquired Immunodeficiency Syndrome Industry Opportunities and Challenges
Table 4. Acquired Immunodeficiency Syndrome Industry Restraints
Table 5. Global Acquired Immunodeficiency Syndrome Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Acquired Immunodeficiency Syndrome Revenue Share by Company (2021-2026)
Table 7. Global Acquired Immunodeficiency Syndrome Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Acquired Immunodeficiency Syndrome Key Company Manufacturing Base & Headquarters
Table 9. Global Acquired Immunodeficiency Syndrome Company, Product Type & Application
Table 10. Global Acquired Immunodeficiency Syndrome Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Acquired Immunodeficiency Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Table 15. Significant Companies of Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 16. Global Acquired Immunodeficiency Syndrome Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Acquired Immunodeficiency Syndrome Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Acquired Immunodeficiency Syndrome Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Acquired Immunodeficiency Syndrome Sales Value Share by Type (2021-2026)
Table 20. Global Acquired Immunodeficiency Syndrome Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Hospital Pharmacy
Table 22. Significant Companies of Retail Pharmacy
Table 23. Significant Companies of Others
Table 24. Global Acquired Immunodeficiency Syndrome Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 25. Global Acquired Immunodeficiency Syndrome Sales Value by Application (2021-2026) & (US$ Million)
Table 26. Global Acquired Immunodeficiency Syndrome Sales Value by Application (2027-2032) & (US$ Million)
Table 27. Global Acquired Immunodeficiency Syndrome Sales Value Share by Application (2021-2026)
Table 28. Global Acquired Immunodeficiency Syndrome Sales Value Share by Application (2027-2032)
Table 29. Global Acquired Immunodeficiency Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 30. Global Acquired Immunodeficiency Syndrome Sales Value by Region (2021-2026) & (US$ Million)
Table 31. Global Acquired Immunodeficiency Syndrome Sales Value Share by Region (2021-2026)
Table 32. Global Acquired Immunodeficiency Syndrome Sales Value by Region (2027-2032) & (US$ Million)
Table 33. Global Acquired Immunodeficiency Syndrome Sales Value Share by Region (2027-2032)
Table 34. Global Acquired Immunodeficiency Syndrome Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 35. Global Acquired Immunodeficiency Syndrome Sales Value by Country (2021-2026) & (US$ Million)
Table 36. Global Acquired Immunodeficiency Syndrome Sales Value Market Share by Country (2021-2026)
Table 37. Global Acquired Immunodeficiency Syndrome Sales Value by Country (2027-2032) & (US$ Million)
Table 38. Global Acquired Immunodeficiency Syndrome Sales Value Market Share by Country (2027-2032)
Table 39. Takeda Company Information
Table 40. Takeda Business Overview
Table 41. Takeda Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 42. Takeda Acquired Immunodeficiency Syndrome Product Portfolio
Table 43. Takeda Recent Development
Table 44. Sanofi Company Information
Table 45. Sanofi Business Overview
Table 46. Sanofi Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. Sanofi Acquired Immunodeficiency Syndrome Product Portfolio
Table 48. Sanofi Recent Development
Table 49. Novartis Company Information
Table 50. Novartis Business Overview
Table 51. Novartis Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 52. Novartis Acquired Immunodeficiency Syndrome Product Portfolio
Table 53. Novartis Recent Development
Table 54. Pfizer Company Information
Table 55. Pfizer Business Overview
Table 56. Pfizer Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 57. Pfizer Acquired Immunodeficiency Syndrome Product Portfolio
Table 58. Pfizer Recent Development
Table 59. Amgen Company Information
Table 60. Amgen Business Overview
Table 61. Amgen Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Amgen Acquired Immunodeficiency Syndrome Product Portfolio
Table 63. Amgen Recent Development
Table 64. Merck KGaA Company Information
Table 65. Merck KGaA Business Overview
Table 66. Merck KGaA Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 67. Merck KGaA Acquired Immunodeficiency Syndrome Product Portfolio
Table 68. Merck KGaA Recent Development
Table 69. Daiichi Sankyo Company Company Information
Table 70. Daiichi Sankyo Company Business Overview
Table 71. Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 72. Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product Portfolio
Table 73. Daiichi Sankyo Company Recent Development
Table 74. Biogen Company Information
Table 75. Biogen Business Overview
Table 76. Biogen Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 77. Biogen Acquired Immunodeficiency Syndrome Product Portfolio
Table 78. Biogen Recent Development
Table 79. AstraZeneca Eli Lilly and Company Company Information
Table 80. AstraZeneca Eli Lilly and Company Business Overview
Table 81. AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 82. AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product Portfolio
Table 83. AstraZeneca Eli Lilly and Company Recent Development
Table 84. Actelion Company Information
Table 85. Actelion Business Overview
Table 86. Actelion Acquired Immunodeficiency Syndrome Revenue (US$ Million) and Gross Margin (2021-2026)
Table 87. Actelion Acquired Immunodeficiency Syndrome Product Portfolio
Table 88. Actelion Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Authors List of This Report
Table 91. Secondary Sources
Table 92. Primary Sources
List of Figures
Figure 1. Acquired Immunodeficiency Syndrome Product Image
Figure 2. Global Acquired Immunodeficiency Syndrome Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Acquired Immunodeficiency Syndrome Market Size (2021-2032) & (US$ Million)
Figure 4. Global Acquired Immunodeficiency Syndrome Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Image
Figure 8. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Image
Figure 9. Global Acquired Immunodeficiency Syndrome Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Acquired Immunodeficiency Syndrome Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Acquired Immunodeficiency Syndrome Sales Value Share by Type (2021-2032)
Figure 12. Hospital Pharmacy Image
Figure 13. Retail Pharmacy Image
Figure 14. Others Image
Figure 15. Global Acquired Immunodeficiency Syndrome Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 16. Global Acquired Immunodeficiency Syndrome Sales Value Share 2021 VS 2025 VS 2032
Figure 17. Global Acquired Immunodeficiency Syndrome Sales Value Share by Application (2021-2032)
Figure 18. Global Acquired Immunodeficiency Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 19. Global Acquired Immunodeficiency Syndrome Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 20. North America Acquired Immunodeficiency Syndrome Sales Value (2021-2032) & (US$ Million)
Figure 21. North America Acquired Immunodeficiency Syndrome Sales Value Share by Country (%), 2025 VS 2032
Figure 22. Europe Acquired Immunodeficiency Syndrome Sales Value (2021-2032) & (US$ Million)
Figure 23. Europe Acquired Immunodeficiency Syndrome Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Asia-Pacific Acquired Immunodeficiency Syndrome Sales Value (2021-2032) & (US$ Million)
Figure 25. Asia-Pacific Acquired Immunodeficiency Syndrome Sales Value Share by Country (%), 2025 VS 2032
Figure 26. South America Acquired Immunodeficiency Syndrome Sales Value (2021-2032) & (US$ Million)
Figure 27. South America Acquired Immunodeficiency Syndrome Sales Value Share by Country (%), 2025 VS 2032
Figure 28. Middle East & Africa Acquired Immunodeficiency Syndrome Sales Value (2021-2032) & (US$ Million)
Figure 29. Middle East & Africa Acquired Immunodeficiency Syndrome Sales Value Share by Country (%), 2025 VS 2032
Figure 30. USA Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 31. USA Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 32. USA Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 33. Canada Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 34. Canada Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 35. Canada Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 36. Mexico Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 37. Mexico Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 38. Mexico Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 39. Germany Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 40. Germany Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 41. Germany Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 42. France Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 43. France Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 44. France Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 45. U.K. Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 46. U.K. Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 47. U.K. Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 48. Italy Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 49. Italy Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 50. Italy Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 51. Spain Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 52. Spain Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 53. Spain Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 54. Russia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 55. Russia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 56. Russia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 57. Netherlands Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 58. Netherlands Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 59. Netherlands Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 60. Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 61. Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 62. Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 63. China Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 64. China Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 65. China Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 66. Japan Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 67. Japan Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 68. Japan Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 69. South Korea Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 70. South Korea Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 71. South Korea Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 72. India Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 73. India Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 74. India Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 75. Australia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 76. Australia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 77. Australia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 78. Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 79. Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 80. Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 81. Brazil Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 82. Brazil Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 83. Brazil Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 84. Argentina Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 85. Argentina Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 86. Argentina Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 87. Chile Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 88. Chile Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 89. Chile Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 90. Colombia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 91. Colombia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 92. Colombia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 93. Peru Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 94. Peru Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 95. Peru Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 96. Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 97. Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 99. Israel Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 100. Israel Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 101. Israel Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 102. UAE Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 103. UAE Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 104. UAE Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 105. Turkey Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 106. Turkey Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 107. Turkey Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 108. Iran Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 109. Iran Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 110. Iran Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 111. Egypt Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 112. Egypt Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 113. Egypt Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 114. Years Considered
Figure 115. Research Process
Figure 116. Key Executives Interviewed
Scope & coverage.
Types
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Others
Companies covered
- Takeda
- Sanofi
- Novartis
- Pfizer
- Amgen
- Merck KGaA
- Daiichi Sankyo Company
- Biogen
- AstraZeneca Eli Lilly and Company
- Actelion
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Acquired Immunodeficiency Syndrome Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Acquired Immunodeficiency Syndrome Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Acquired Immunodeficiency Syndrome Market Dynamics
- 2.1 Acquired Immunodeficiency Syndrome Industry Trends
- 2.2 Acquired Immunodeficiency Syndrome Industry Drivers
- 2.3 Acquired Immunodeficiency Syndrome Industry Opportunities and Challenges
- 2.4 Acquired Immunodeficiency Syndrome Industry Restraints
3 Acquired Immunodeficiency Syndrome Market by Company
- 3.1 Global Acquired Immunodeficiency Syndrome Company Revenue Ranking in 2025
- 3.2 Global Acquired Immunodeficiency Syndrome Revenue by Company (2021-2026)
- 3.3 Global Acquired Immunodeficiency Syndrome Company Ranking (2024-2026)
- 3.4 Global Acquired Immunodeficiency Syndrome Company Manufacturing Base and Headquarters
- 3.5 Global Acquired Immunodeficiency Syndrome Company Product Type and Application
- 3.6 Global Acquired Immunodeficiency Syndrome Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Acquired Immunodeficiency Syndrome Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Acquired Immunodeficiency Syndrome Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Acquired Immunodeficiency Syndrome Market by Type
- 4.1 Acquired Immunodeficiency Syndrome Type Introduction
- 4.1.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 4.1.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 4.2 Global Acquired Immunodeficiency Syndrome Sales Value by Type
- 4.2.1 Global Acquired Immunodeficiency Syndrome Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Acquired Immunodeficiency Syndrome Sales Value by Type (2021-2032)
- 4.2.3 Global Acquired Immunodeficiency Syndrome Sales Value Share by Type (2021-2032)
5 Acquired Immunodeficiency Syndrome Market by Application
- 5.1 Acquired Immunodeficiency Syndrome Application Introduction
- 5.1.1 Hospital Pharmacy
- 5.1.2 Retail Pharmacy
- 5.1.3 Others
- 5.2 Global Acquired Immunodeficiency Syndrome Sales Value by Application
- 5.2.1 Global Acquired Immunodeficiency Syndrome Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Acquired Immunodeficiency Syndrome Sales Value by Application (2021-2032)
- 5.2.3 Global Acquired Immunodeficiency Syndrome Sales Value Share by Application (2021-2032)
6 Acquired Immunodeficiency Syndrome Regional Value Analysis
- 6.1 Global Acquired Immunodeficiency Syndrome Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Acquired Immunodeficiency Syndrome Sales Value by Region (2021-2032)
- 6.2.1 Global Acquired Immunodeficiency Syndrome Sales Value by Region: 2021-2026
- 6.2.2 Global Acquired Immunodeficiency Syndrome Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Acquired Immunodeficiency Syndrome Sales Value (2021-2032)
- 6.3.2 North America Acquired Immunodeficiency Syndrome Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Acquired Immunodeficiency Syndrome Sales Value (2021-2032)
- 6.4.2 Europe Acquired Immunodeficiency Syndrome Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Acquired Immunodeficiency Syndrome Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Acquired Immunodeficiency Syndrome Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Acquired Immunodeficiency Syndrome Sales Value (2021-2032)
- 6.6.2 South America Acquired Immunodeficiency Syndrome Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Acquired Immunodeficiency Syndrome Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Acquired Immunodeficiency Syndrome Sales Value Share by Country, 2025 VS 2032
7 Acquired Immunodeficiency Syndrome Country-level Value Analysis
- 7.1 Global Acquired Immunodeficiency Syndrome Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Acquired Immunodeficiency Syndrome Sales Value by Country (2021-2032)
- 7.2.1 Global Acquired Immunodeficiency Syndrome Sales Value by Country (2021-2026)
- 7.2.2 Global Acquired Immunodeficiency Syndrome Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.7.2 France Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.14.2 China Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.17.2 India Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Acquired Immunodeficiency Syndrome Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Acquired Immunodeficiency Syndrome Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Acquired Immunodeficiency Syndrome Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Acquired Immunodeficiency Syndrome Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Acquired Immunodeficiency Syndrome Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Acquired Immunodeficiency Syndrome Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Pfizer
- 8.4.1 Pfizer Company Information
- 8.4.2 Pfizer Business Overview
- 8.4.3 Pfizer Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Acquired Immunodeficiency Syndrome Product Portfolio
- 8.4.5 Pfizer Recent Developments
- 8.5 Amgen
- 8.5.1 Amgen Company Information
- 8.5.2 Amgen Business Overview
- 8.5.3 Amgen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.5.4 Amgen Acquired Immunodeficiency Syndrome Product Portfolio
- 8.5.5 Amgen Recent Developments
- 8.6 Merck KGaA
- 8.6.1 Merck KGaA Company Information
- 8.6.2 Merck KGaA Business Overview
- 8.6.3 Merck KGaA Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.6.4 Merck KGaA Acquired Immunodeficiency Syndrome Product Portfolio
- 8.6.5 Merck KGaA Recent Developments
- 8.7 Daiichi Sankyo Company
- 8.7.1 Daiichi Sankyo Company Company Information
- 8.7.2 Daiichi Sankyo Company Business Overview
- 8.7.3 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.7.4 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product Portfolio
- 8.7.5 Daiichi Sankyo Company Recent Developments
- 8.8 Biogen
- 8.8.1 Biogen Company Information
- 8.8.2 Biogen Business Overview
- 8.8.3 Biogen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.8.4 Biogen Acquired Immunodeficiency Syndrome Product Portfolio
- 8.8.5 Biogen Recent Developments
- 8.9 AstraZeneca Eli Lilly and Company
- 8.9.1 AstraZeneca Eli Lilly and Company Company Information
- 8.9.2 AstraZeneca Eli Lilly and Company Business Overview
- 8.9.3 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.9.4 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product Portfolio
- 8.9.5 AstraZeneca Eli Lilly and Company Recent Developments
- 8.10 Actelion
- 8.10.1 Actelion Company Information
- 8.10.2 Actelion Business Overview
- 8.10.3 Actelion Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
- 8.10.4 Actelion Acquired Immunodeficiency Syndrome Product Portfolio
- 8.10.5 Actelion Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst